Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20332426 | 0.81 | LMNA (0.58) | ALDH1A1HRH4KDM4EPRMT6 | |
| SCHEMBL13937097 | 0.81 | SIGMAR1 (0.52) | HRH3 | |
| SCHEMBL18202690 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4EATMNPSR1L3MBTL1 | |
| SCHEMBL25171162 | 0.80 | HRH3 (0.59) | ALDH1A1HRH3HRH4KDM4ECHRNB2 | |
| SCHEMBL14566680 | 0.80 | HRH3 (0.54) | ALDH1A1HRH3HRH4KDM4ECHRNB2 | |
| SCHEMBL4267512 | 0.79 | ALDH1A1 (0.59) | ALDH1A1HRH3HRH4KDM4ECHRNB2 | |
| Hydrochloric Acid SCHEMBL23296000 | 0.79 | LMNA (0.56) | ALDH1A1HRH4KDM4EATMNPSR1 | |
| SCHEMBL30635452 | 0.78 | HRH3 (0.52) | ALDH1A1HRH3HRH4KDM4ECHRNB2 | |
| SCHEMBL20311330 | 0.78 | HRH3 (0.56) | ALDH1A1HRH3HRH4KDM4ECHRNB2 | |
| SCHEMBL18211891 | 0.78 | HRH3 (0.50) | ALDH1A1HRH3HRH4KDM4ECHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | ALDH1A1 2942/4885HRH3 4782/4885HRH4 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.